Drug discontinuation: Tazemetostat Hydrobromide Tablet (TAZVERIK)
FDA lists 1 presentation as To Be Discontinued. Companies: Epizyme, Inc. (An Ipsen Company).
- Published by source
- 2026-03-27
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Epizyme, Inc. (An Ipsen Company)
- Products
- Tazemetostat Hydrobromide Tablet TAZVERIK
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- Discontinuation of the manufacture of the drug product
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-03-27
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #1073 | new | 2026-10-22 | c70ea8c2802d…f61de8 | ad514dd1e20f…3fe034 |
Chain head: #1076 8ad5adc30b9b…88ce20